A purple pill marked with the imprint D12 (specifically stamped M D12) is Doxazosin Mesylate 8 mg, a prescription medication manufactured by Mylan Pharmaceuticals.
(Note: “Purple Pills” is also the title of a famous 2001 hip-hop single by Eminem’s group D12, but medically, the physical purple tablet bearing the code “D12” refers to Doxazosin).
Identification
Attribute – Specification
- Active Ingredient – Doxazosin Mesylate (equivalent to 8 mg Doxazosin base)
- Imprint – M on one side, D12 on the reverse side
- Color & Shape – Purple, round, biconvex tablet
- Diameter – Approximately 9 mm
- Drug Class – Peripherally acting selective adrenergic receptor antagonist (Alpha-blocker)
- Manufacturer – Mylan Pharmaceuticals Inc.
Mechanism of Action
Doxazosin selectively and competitively binds to postsynaptic adrenergic receptors:
- For Hypertension: Inhibiting vascular receptors prevents norepinephrine from inducing vasoconstriction in peripheral arterioles and veins. This leads to peripheral vasodilation, reducing systemic vascular resistance (afterload) and lowering blood pressure.
- For Benign Prostatic Hyperplasia (BPH): Doxazosin blocks receptors concentrated in the stromal tissue and smooth muscle of the prostate gland, prostatic capsule, and bladder neck. Relaxing this smooth muscle reduces bladder outlet obstruction and improves urinary flow without altering prostate size.
Indications and Dosage
Doxazosin is primarily indicated for the treatment of Benign Prostatic Hyperplasia (BPH) and Essential Hypertension (either as monotherapy or in combination with other antihypertensive agents).
- Standard Starting Dose: 1 mg orally once daily (usually taken at bedtime to reduce the risk of fainting or severe hypotension).
- Titration Schedule: Dose is titrated upwards in intervals of 1 to 2 weeks depending on clinical response and tolerability (e.g., 1 mg rightarrow 2 mg \rightarrow 4 mg \rightarrow 8 mg).
- 8 mg Tablet (M D12): The 8 mg purple tablet represents the typical target maintenance dose for BPH or moderate-to-severe hypertension. The absolute maximum daily dose for BPH is 8 mg; for severe hypertension, titration may rarely reach up to 16 mg daily under specialist care.
- Administration: Take once daily with or without food.
Side Effects
Common Side Effects
- Dizziness, lightheadedness, and vertigo
- Somnolence (drowsiness) and fatigue
- Headache
- Peripheral edema (fluid retention in lower legs or ankles)
- Nasal congestion
- Asthenia (general physical weakness)
Serious Side Effects
- Severe Orthostatic Hypotension: Marked blood pressure drop upon standing, leading to syncope (fainting).
- Priapism: A rare but painful, prolonged penile erection lasting longer than 4 hours. This requires immediate emergency medical intervention to prevent permanent erectile tissue damage.
- Intraoperative Floppy Iris Syndrome (IFIS): Complication during cataract or glaucoma eye surgery.
- Severe Allergic Reactions: Rash, pruritus, angioedema, or difficulty breathing.
Precautions and Warnings
- First-Dose Phenomenon: Marked hypotension and syncope can occur within 2 to 6 hours following the first dose or after rapid dose escalation. Patients should sit down or lie flat if feeling dizzy and avoid sudden postural changes.
- Cataract and Glaucoma Surgery (IFIS): Patients planning cataract or glaucoma surgery must notify their ophthalmologist prior to the procedure. Alpha-1 blockers can cause the iris to become flaccid during surgery, increasing complication rates.
- Hepatic Impairment: Doxazosin is heavily metabolized by the liver. Use with caution in patients with hepatic dysfunction or cirrhosis.
- Prostate Cancer Screening: Prior to initiating doxazosin for BPH, underlying carcinoma of the prostate should be ruled out, as both conditions often coexist and produce identical symptoms.
- Drug Interactions:
- PDE-5 Inhibitors (e.g., Sildenafil, Tadalafil): Concomitant use can cause additive vasodilation resulting in profound, life-threatening hypotension.
- Other Antihypertensives: Concomitant use with beta-blockers, ACE inhibitors, or diuretics increases the risk of symptomatic hypotension.
- Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Clarithromycin): May increase plasma concentrations of doxazosin.